R-5260

}}

}}

”’R-5260”’ is an opioid drug from the [[orphine]] series, which is an [[derivative (chemistry)|derivative]] of the [[opioid]] [[analgesic]] [[norpipanone]], but with the [[piperidine|piperidine ring]] fused with a [[spiro compound|spiro]] [[heterocycle]]. It was developed by [[Janssen Pharmaceutica]], and is a highly potent opioid around 10x the potency of [[fentanyl]]. It is related to other potent opioid derivatives such as [[dipipanone]], [[bezitramide]], [[R-4066]] and [[spirochlorphine]], and is also related to [[dopamine antagonist]] [[neuroleptic]] drugs such as [[spiperone]] and [[fluspirilene]], although R-5260 does not have any dopamine antagonist activity itself.<ref>{{cite journal | vauthors = Leysen J, Tollenaere JP, Koch MH, Laduron P | title = Differentiation of opiate and neuroleptic receptor binding in rat brain | journal = European Journal of Pharmacology | volume = 43 | issue = 3 | pages = 253–267 | date = June 1977 | pmid = 194781 | doi = 10.1016/0014-2999(77)90025-5 }}</ref><ref name=”Gorissen_1980″>{{cite journal | vauthors = Gorissen H, Ilien B, Aerts G, Laduron P | title = Differentiation of solubilized dopamine receptors from spirodecanone binding sites in rat striatum | journal = FEBS Letters | volume = 121 | issue = 1 | pages = 133–138 | date = November 1980 | pmid = 6161839 | doi = 10.1016/0014-5793(80)81282-8 | bibcode = 1980FEBSL.121..133G }}</ref>

”’R-5260”’ is an opioid drug from the [[orphine]] series, which is [[derivative (chemistry)|derivative]] of the [[opioid]] [[analgesic]] [[norpipanone]], but with the [[piperidine|piperidine ring]] fused with a [[spiro compound|spiro]] [[heterocycle]]. It was developed by [[Janssen Pharmaceutica]], and is a highly potent opioid around 10x the potency of [[fentanyl]]. It is related to other potent opioid derivatives such as [[dipipanone]], [[bezitramide]], [[R-4066]] and [[spirochlorphine]], and is also related to [[dopamine antagonist]] [[neuroleptic]] drugs such as [[spiperone]] and [[fluspirilene]], although R-5260 does not have any dopamine antagonist activity itself.<ref>{{cite journal | vauthors = Leysen J, Tollenaere JP, Koch MH, Laduron P | title = Differentiation of opiate and neuroleptic receptor binding in rat brain | journal = European Journal of Pharmacology | volume = 43 | issue = 3 | pages = 253–267 | date = June 1977 | pmid = 194781 | doi = 10.1016/0014-2999(77)90025-5 }}</ref><ref name=”Gorissen_1980″>{{cite journal | vauthors = Gorissen H, Ilien B, Aerts G, Laduron P | title = Differentiation of solubilized dopamine receptors from spirodecanone binding sites in rat striatum | journal = FEBS Letters | volume = 121 | issue = 1 | pages = 133–138 | date = November 1980 | pmid = 6161839 | doi = 10.1016/0014-5793(80)81282-8 | bibcode = 1980FEBSL.121..133G }}</ref>

== References ==

== References ==